ClinicalTrials.gov record
Terminated Phase 4 Interventional Results available

A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease

ClinicalTrials.gov ID: NCT03119662

Public ClinicalTrials.gov record NCT03119662. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 9:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Parallel-Group, Placebo-Controlled Randomized Study Investigating the Effect of Intravenous Iso-osmolar Iodinated Contrast Material Iodixanol (Visipaque™ Injection 320 mgI/mL) on Renal Function in Adults With Chronic Kidney Disease (CKD) Stage III or Stage IV Who Have Undergone Endovascular Aneurysm Repair (EVAR)

Study identification

NCT ID
NCT03119662
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 4
Lead sponsor
GE Healthcare
Industry
Enrollment
4 participants

Conditions and interventions

Interventions

  • Placebos Drug
  • Visipaque Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 7, 2018
Primary completion
Sep 12, 2018
Completion
Oct 18, 2018
Last update posted
Dec 16, 2019

2018

United States locations

U.S. sites
17
U.S. states
14
U.S. cities
17
Facility City State ZIP Site status
University Hospital Birmingham Alabama 35233
: Aventiv Research Inc. Mesa Arizona 85210
Central Arkansas Veteran's Healthcare System Little Rock Arkansas 72205
Alliance Research Centers Laguna Hills California 92653
Universal Axon Clinical Research, LLC Doral Florida 33166
Jacksonville Center for Clinical Research Jacksonville Florida 32216
University of South Florida - South Tampa Campus Tampa Florida 33606
University of Iowa Hospitals and Clinics Iowa City Iowa 52242
Norton Hospital Louisville Kentucky 40202
Boston University Medical Center/Boston Medical Center Boston Massachusetts 02118
The Duluth Clinic, Ltd. Duluth Minnesota 55805
Mount Sinai West New York New York 10019
University of North Carolina at Chapel Hill Clinical Translational Research Center Chapel Hill North Carolina 27599
Wake Forest Baptist Health Winston-Salem North Carolina 27157
Rhode Island Hospital Providence Rhode Island 02903
UT Southwestern Medical Center Dallas Texas 75390
University of Vermont Medical Center Burlington Vermont 05401

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03119662, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2019 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03119662 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →